EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026

Key Takeaways

• EMA’s CHMP recommended conditional marketing authorization for Adstiladrin (nadofaragene firadenovec) gene therapy for bladder cancer
• Treatment targets adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
• Recommendation was part of five new medicines approved at CHMP’s March 23-26, 2026 meeting

---

EMA Advances Gene Therapy for Bladder Cancer Patients

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended conditional marketing authorization for Adstiladrin (nadofaragene firadenovec) during its March 23-26, 2026 meeting, marking a significant advancement in bladder cancer treatment options.

Treatment Details and Patient Population

Adstiladrin represents a gene therapy approach specifically designed for adult patients with Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. This patient population has historically faced limited treatment options after BCG therapy failure.

The conditional marketing authorization pathway allows for earlier patient access to promising treatments while additional data collection continues. This regulatory approach is particularly valuable for oncology treatments addressing unmet medical needs.

Market Impact and Clinical Significance

Bladder cancer affects approximately 573,000 people globally each year, with non-muscle invasive bladder cancer representing about 75% of all bladder cancer cases. BCG therapy has been the standard treatment, but up to 40% of patients may not respond or become unresponsive to this treatment.

Gene therapy approaches like Adstiladrin offer a novel mechanism of action that could provide new hope for patients who have exhausted conventional treatment options. The therapy’s approval could establish a new treatment paradigm in urology and oncology.

Regulatory Timeline and Next Steps

Following the CHMP’s positive recommendation, the European Commission will make the final decision on marketing authorization, typically within 67 days. If approved, Adstiladrin would join a growing portfolio of gene therapies available in the European Union.

The March 2026 CHMP meeting resulted in recommendations for five new medicines, demonstrating continued innovation in pharmaceutical development and regulatory approval processes across multiple therapeutic areas.

---

Frequently Asked Questions

What does this mean for bladder cancer patients?

Patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ may soon have access to a new gene therapy treatment option that works differently from conventional therapies.

When will Adstiladrin be available in Europe?

Following CHMP’s recommendation, the European Commission will make the final approval decision within approximately 67 days. If approved, availability will depend on individual country pricing and reimbursement decisions.

How does Adstiladrin compare to existing bladder cancer treatments?

Adstiladrin is a gene therapy that offers a novel mechanism of action for patients who haven’t responded to BCG therapy, potentially providing an option where limited alternatives previously existed.